All post‐race samples shall be subjected to instrumental screening analysis as described in below. A limited number of Enzyme Linked Immunosorbent Assay (ELISA) tests, for substances lacking a validated instrumental screening method, may also be proposed. The Contractor shall provide justification for each ELISA test it intends to apply to NRGC’s samples. The Contractor must demonstrate that the sensitivity of proposed ELISA test kits is relevant to NRGC’s regulation of the listed substances. ELISA tests may not be rotated; all proposed tests must be applied to all post‐race samples. The use of thin‐layer chromatography is not permitted. Samples may not be pooled. All samples shall be subjected to the same scope of analysis with respect to threshold substances. The post‐race testing menu for all tested samples shall include instrumental screening analysis with a scope of testing encompassing all Controlled Therapeutic Medications (as published in the Racing Commissioners International [RCI] Model Rules Chapter 11) with testing sensitivities at or below NRGC thresholds...
